Xilio Therapeutics, Inc.
About Xilio Therapeutics, Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $43.8M
- Net income
- -$35.0M
- Total assets
- $154.7M
- Market cap
- $50.6M
- Operating margin
- -95.9%
- Net margin
- -80.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $43.8M
- Operating expenses
- $85.7M
- Operating income
- -$42.0M
- Income tax
- $0
- Net income
- -$35.0M
- EPS (basic)
- $-4.19
- EPS (diluted)
- $-4.19
Balance sheet
- Total assets
- $154.7M
- Current assets
- $145.0M
- Total liabilities
- $119.4M
- Current liabilities
- $56.3M
- Shareholders’ equity
- $35.3M
Cash flow
- Operating cash flow
- -$5.0M
- Investing cash flow
- -$518.0K
- Financing cash flow
- $87.8M
- Net cash flow
- $82.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $50.6M
- EPS (diluted)
- $-4.19
- Shares outstanding
- 6.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 22, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $35.0M in FY2025.
- Trading 52% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Xilio Therapeutics, Inc..
Write a review
News about Xilio Therapeutics, Inc.
News & sentiment via Polygon.io
